Evidence map›Paper›PMID 34113569›Full record

ArticleFrontiers in oncology2021

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Ying Zhang, Jiaqi Li, Xiaoyan Lou, Xiaochen Chen, Zhou Yu, Liqing Kang, Jia Chen, Jin Zhou, Xiangping Zong, Zhen Yang and 10 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03196830 (Safety and Efficacy of Chimeric Antigen Receptor T Cell), which is not on this map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
3.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03196830 phase2completednot on this map

Safety and Efficacy of Chimeric Antigen Receptor T Cell (CAR-T) Treating Relaspe/Refractory CD19/CD20/CD22/CD30 Postive Non-Hodgkin Lymphoma

TypeinterventionalSponsorThe First Affiliated Hospital of Soochow UniversityRan2017 to 2024Enrolled168ConditionsRelapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, CAR - T CD19/CD20/CD22/CD30ArmsCAR-T
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Ying ZhangJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jiaqi LiJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaoyan LouShanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China.
Xiaochen ChenJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhou YuShanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China.
Liqing KangShanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China.
Jia ChenJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jin ZhouJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiangping ZongJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhen YangJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Minghao LiInstitute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
Nan XuInstitute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
Sixun JiaJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Hongzhi GengJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Guanghua ChenJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Haiping DaiJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaowen TangJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Lei YuShanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China.
Depei WuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Caixia LiJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CNEast China Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge to overcome. Here, we report the clinical results and the pharmacokinetics of bispecific CD19/22 CAR T in patients with R/R B-NHL.

methodsWe performed a prospective, single-arm study of bispecific CD19/22 CAR T cells in R/R B-NHL. We analyzed the safety and efficacy and investigated the kinetic profiles of the CAR T cells. CAR transgene levels were measured using quantitative polymerase chain reaction, and correlation analyses of pharmacodynamic markers and product characteristics, disease conditions, clinical efficacy and adverse events were performed.

resultsFrom August 2017 to September 2020, a total of 32 patients with CD19/22 CAR T administration were analyzed. The overall response rate was 79.3%, and the complete response rate was 34.5%. The progression-free survival (PFS) and overall survival (OS) rates at 12 months were 40.0% and 63.3%, respectively. Among patients who had a CR at 3 months, the PFS and OS rates at 12 months were 66.7% and 100%, respectively. Severe cytokine release syndrome (sCRS) (grade 3 and higher) occurred in nine patients (28.1%). Grade 3 or higher neurologic events occurred in four patients (12.5%). One patient died from irreversible severe CRS-associated acute kidney injury. Long-term CAR T cells persistence correlated with clinical efficacy (133 days vs 22 days, P = 0.004). Patients treated with more than three prior therapies and presenting extranodal organ involvement had lower maximal concentration (C

conclusionsThis study demonstrates the safety and potential clinical efficacy of bispecific CD19/22 CAR T cells in patients with R/R B-NHL and highlights the importance of measuring kinetic parameters in PB to predict efficacy and safety in clinical applications of CAR T cell therapy. CLINICAL

trial registrationhttps://www.clinicaltrials.gov/ct2/show/NCT03196830, identifier NCT03196830.

Indexed as

B cell non-Hodgkin lymphomabispecific chimeric antigen receptorCD19/22cellular kineticsrelapsed or refractory

Identifiers

PMID34113569
PMCPMC8185372
OpenAlexW3165807606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.